Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns

Conditions studied

Metastatic Breast Cancer

About this study

The purpose of this observational study is to learn about the HER2 heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer. The main question it aims to answer is: \- Does the heterogeneity of HER2 expression level and spatial distribution in different tissues affect the efficacy of trastuzumab deruxtecan in metastatic breast cancer?

Interventions

• Drug: Trastuzumab Deruxtecan — The patients received Trastuzumab Deruxtecan at a dose of 5.4 mg/kg every 3 weeks until disease progression or unacceptable adverse effects occurred.

Primary outcomes

• Progression-free survival (PFS) (From date of T-DXd treatment initiation until the date of first documented disease progression or date of death from any cause, whichever came first, assessed up to 60 months.)

Eligibility information

Study locations

• Yale Cancer Center, New Haven, Connecticut 06510 United States
• Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215 United States
• Fujian Cancer Hospital, Fujian Medical University, Fuzhou, Fujian China
• The 10th Affiliated Hospital of Southern Medical University, Dongguan, Guangdong China
• The First People's Hospital of Foshan, Foshan, Guangdong China
• The Sixth Affiliated Hospital, School of Medicine, South China University of Technology., Foshan, Guangdong China
• Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060 China
• The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, Guangdong 511400 China
• Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong China
• The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong China

Showing 10 of 26 reported sites. See the official listing for all locations.